WHAT SLEEP APNEA COULD BE DOING TO YOUR BRAIN WHILE YOU SLEEP, FROM MEMORY TO DEMENTIA RISK

Snoring, tossing and waking up tired can feel like ordinary adult life. A growing body of research suggests those nightly disruptions may be quietly reshaping the brain and raising the long-term risk of dementia. Sleep apnea, a condition in which breathing repeatedly stops during sleep, affects roughly 29 million Americans, and most of them have no idea they have it.

The gap is especially wide for women. Nearly one in five women live with obstructive sleep apnea, yet nine out of 10 remain undiagnosed.

How sleep apnea works

In healthy sleep, the airway stays open. In sleep apnea, it does not.

“When a normal person falls asleep who doesn’t have sleep apnea, the airway stays open. But in someone who has sleep apnea, the airway does not stay open and an individual stops breathing,” Dr. Aatif Husain, professor of neurology and chief of the Division of Epilepsy, Sleep and Clinical Neurophysiology at Duke University Medical Center, told GQ.

Each apnea event lasts at least 10 seconds. The brain then jolts the body awake to restart breathing, and the cycle can repeat 5 to 100 times an hour. Loud snoring is a common signal, though Johns Hopkins notes you can snore heavily without having apnea and have apnea without much snoring.

Why sleep apnea threatens the brain

The damage is not only cardiovascular, though it is that too. Untreated apnea is tied to heart disease, heart failure and stroke, according to Dr. Heidi Doss Riney, chief medical officer at Nox Health and medical director of Fusion Sleep Center in Georgia. She also links it to hypertension, diabetes and obesity, in comments published by Nox Medical.

The brain takes a distinct hit each night. “Repeated apnea episodes cause drops in oxygen levels in the brain. This triggers a panic response, raising blood pressure and heart rate. Over time, this accumulated stress damages blood vessels and the brain itself,” said Dr. Alberto Ramos, professor in the Sleep Medicine Division at the University of Miami Miller School of Medicine.

Ramos’s most recent study, involving more than 3,000 participants, found that sleep apnea can shrink important brain regions, including the hippocampus.

“The hippocampus is key for consolidating memory. We also observed changes in small blood vessels, which increase the risk of dementia and Alzheimer’s over time,” Ramos said.

The dementia connection

The evidence is stacking up. A meta-analysis of nine observational studies found that obstructive sleep apnea may more than double the risk of cognitive decline or Alzheimer’s disease. A separate review of five studies found apnea is more common in Alzheimer’s patients, and other work suggests cognitively healthy older adults with apnea show altered levels of Alzheimer’s biomarkers that worsen over time.

Researchers point to three overlapping pathways. Repeated drops in blood oxygen damage brain cells. Apnea drives up rates of hypertension, cardiovascular disease and depression, all independent Alzheimer’s risk factors. And fragmented sleep blocks the memory consolidation the brain depends on each night.

Ramos argues there is a window to act. “The ideal time to identify and treat these breathing problems is between 40 and 50 years old, when it’s still possible to prevent brain changes linked to years of poor-quality sleep,” he said.

How to get diagnosed

Most patients start with a primary care visit, then a referral to a sleep specialist, though insurance rules vary. From there, the doctor may order an in-lab sleep study or a home sleep apnea test, which patients pick up, run overnight and return.

A newer at-home option, the Happy Ring from Happy Health, packages an FDA-cleared sleep test with a board-certified sleep physician consultation. Loud snoring, daytime sleepiness and obesity are common signs. Being male and older age also raise the risk.

Current and coming treatments

The standard treatment remains the CPAP machine, which pushes a steady stream of air through a mask to keep the airway open. Oral appliances that pull the jaw forward are another option.

A pill may be next. A Phase 3 trial published in May 2026 in the American Journal of Respiratory and Critical Care Medicine tested AD109, a once-nightly combination of aroxybutynin and atomoxetine developed by Apnimed. Compared with placebo, the drug produced marked improvements in airway obstruction and oxygenation. The authors wrote that AD109 could have “utility across all levels of disease severity and a wide range of weight classes” and “may fill a large unmet need in providing patients with a pharmacologic therapy targeting the neuromuscular dysfunction underlying OSA pathogenesis.” Apnimed is seeking FDA approval and hopes for a decision next year.

This article was created by content specialists using various tools, including AI.

2026-08-05T01:03:54Z